{"schema_version":"secwatch.filing_event.v1","accession":"0001860742-24-000011","form_type":"8-K","ticker":"BLCO","cik":"0001860742","company_name":"Bausch & Lomb Corp","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.987974+00:00","generated_at":"2026-05-31T14:30:21.600748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bausch + Lomb Q2 revenue $1.216B (+17% YoY); GAAP net loss $151M; raises FY2024 guidance","bullets":["Revenue $1.216B, up 17% reported and 20% constant currency vs Q2 2023.","GAAP net loss attributable to BLCO $151M; adjusted EPS $0.13 (vs $0.18 a year ago).","Pharmaceuticals segment revenue surged 60% YoY to $310M, driven by XIIDRA acquisition and MIEBO launch.","Raised FY2024 revenue guidance to $4.7-4.8B (prev $4.6-4.7B) and adjusted EBITDA to $850-900M.","Adjusted EBITDA (non-GAAP) $209M, up from $179M in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001860742-24-000011","json":"https://secwatch.observer/filing/0001860742-24-000011.json","markdown":"https://secwatch.observer/filing/0001860742-24-000011.md","text":"https://secwatch.observer/filing/0001860742-24-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860742/000186074224000011/0001860742-24-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860742/000186074224000011/blco-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:30:21.600748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}